Clinically additive effect between doxazosin and amlodipine in the treatment of essential hypertension

Basit Öğe Kaydı
dc.contributor.authorNalbantgil, S
dc.contributor.authorNalbantgil, I
dc.contributor.authorOnder, R
dc.date.accessioned2019-10-27T18:22:32Z
dc.date.available2019-10-27T18:22:32Z
dc.date.issued2000
dc.departmentEge Üniversitesien_US
dc.description.abstractThe Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure has reported that combinations of low doses of antihypertensive agents from different classes may provide additional antihypertensive efficacy and minimize the likelihood of dose-dependent adverse effects. Doxazosin and amlodipine, alone and in combination, were compared for efficacy in reducing blood pressure (BP) in 75 patients with predominantly moderate (Stage 2) hypertension. This was a double-blind, randomized, crossover study. After a 2-week washout period, patients in group A (n = 37) received amlodipine 10 mg and patients in group B (n = 38) received doxazosin 4 mg for 6 weeks. All patients then received reduced-dose combination therapy (amlodipine 5 mg and doxazosin 2 mg) for 6 weeks. Subsequently, patients received 6 weeks of monotherapy with the alternate medication (group A received doxazosin 4 mg and group B received amlodipine 10 mg). During both monotherapy periods, doxazosin and amlodipine significantly reduced systolic and diastolic BP (P < .001 v baseline). BP further decreased with combination therapy (P < .01 v monotherapy). The percentage of patients with Stage 2 hypertension who achieved a target BP of < 140/ < 90 mm Hg increased from 78% with monotherapy to 94% with combination therapy. Fewer adverse effects were observed during combination therapy. It is concluded that there is an additional fall in blood pressure when reduced doses of doxazosin and amlodipine are used in combination for the treatment of hypertension, suggesting that doxazosin should be considered as an effective add-on treatment to calcium-channel blockers. (C) 2000 American Journal of Hypertension, Ltd.en_US
dc.identifier.doi10.1016/S0895-7061(99)00279-4en_US
dc.identifier.endpage926en_US
dc.identifier.issn0895-7061
dc.identifier.issue8en_US
dc.identifier.pmid10950401en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage921en_US
dc.identifier.urihttps://doi.org/10.1016/S0895-7061(99)00279-4
dc.identifier.urihttps://hdl.handle.net/11454/36016
dc.identifier.volume13en_US
dc.identifier.wosWOS:000088586200009en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofAmerican Journal of Hypertensionen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjecthypertensionen_US
dc.subjectcombination therapyen_US
dc.subjectmonotherapyen_US
dc.subjectdoxazosinen_US
dc.subjectamlodipineen_US
dc.titleClinically additive effect between doxazosin and amlodipine in the treatment of essential hypertensionen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu